Between February 1995 and July 1999 25 pediatric patients (8 months to 14 years old) underwent peripheral blood stem cell transplantation (PBSCT) from an HLA-identical sibling donor. Diagnoses included ALL (17), non-ALL (6), and non-malignant disease (2). GVHD prophylaxis consisted of cyclosporine plus methotrexate (15), only cyclosporine (8), cyclosporine plus prednisone (1), or nothing (1). All donors (6 months to 41 years old) received G-CSF at 10 g/kg/day subcutaneously for 4-5 days and on day 5 underwent large volume leukapheresis. Median number of CD34 + and CD3
Initially considered as a second-line procedure with limited indications, [1] [2] [3] [4] over the last few years allogeneic peripheral blood stem cell transplantation (allo-PBSCT) has been increasingly performed and currently it has been adopted by several institutions as a first transplantation approach in adult patients with hematological malignancies and an HLA-identical sibling donor. Most of the studies published have recognized the advantages of the procedure for both recipient and donor, although there are still controversies regarding long-term benefits and safety. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] In the pediatric setting the use of this technology has been hampered, mainly due to ethical concerns regarding safety of the donation procedure and technical difficulties especially when low-weight donors are involved. Experience with pediatric HLA-identical sibling PBSCT is limited to a small number of specialized pediatric transplantation teams that have developed different approaches to resolve the demands of the procedure in these especial circumstances. [17] [18] [19] [20] [21] [22] The efficacy of G-CSF for mobilization of hematopoietic progenitors in healthy pediatric donors has been shown and its short-term side-effect profile has been reported as acceptable. [23] [24] [25] [26] However, information about long-term safety of G-CSF in normal children is very limited, and only a few reports involving normal adult donors have been published. [25] [26] [27] [28] [29] [30] [31] The potential complications of central venous access that is frequently needed for the collection in children as well as the risks of the apheresis procedure are also of concern. Feasibility of the procedure has been proven in even the smallest donors, [32] [33] [34] [35] but methods of mobilization and collection vary between institutions and there are no commonly accepted recommendations for indications or contraindications in pediatric allo-PBSCT other than the institution's own experience. There are no defined eligibility criteria for donation in children, ethical questions have not been completely resolved and long-term benefits of the procedure are still under discussion.
The following report is intended to show the experience with HLA-identical sibling allo-PBSCT at the Niño Jesus Children's Hospital Pediatric Bone Marrow Transplant Unit. Mobilization and collection procedures for allo-PBSCT were designed and performed according to the center's previous experience gained with pediatric autologous PBSCT. 36 The feasibility and safety of this approach and the clinical outcomes of the procedure were analyzed.
Patients, donors and methods

Study design and ethical considerations
A prospective non-randomized pilot study was designed and conducted at a single pediatric medical institution. Protocol procedures for allogeneic PBSC transplantation were approved by the Institutional Ethical Committee. Advantages and disadvantages of the procedure (for both donor and recipient) were explained appropriately to the parents or legal guardians, according to the center's own experience as well as the current literature. Appropriate informed consent was obtained for G-CSF mobilization, central catheter placement and large volume leukapheresis as well as PBSC transplantation. When the parents rejected the allo-PBSC procedure, the donor underwent a bone marrow harvest and the patient was excluded from the study.
Patients
Between February 1995 and July 1999, 25 patients (16 males and eight females) from 8 months to 14 years of age received an allogeneic PBSCT for the treatment of a hematological disease. All patients received stem cells from an HLA-identical sibling donor, one of them from his identical twin brother. Patient characteristics are summarized in Table 1 .
Donors
There were 25 donors; eight males and 16 females, 6 months to 41 (median 10) years of age. All were HLA identical with their respective recipients. Fourteen of the donors were Ͻ18 years old, ages between 6 months and 13 years (median 4.5), four of them weighing less than 15 kg. All donors were found to be healthy in a complete medical evaluation done pre-donation. G-CSF (Neupogen; Amgen, Thousand Oaks, CA, USA) was given subcutaneously once a day at 10 g/kg/day for 4-5 days before the apheresis procedure. No significant side-effects during G-CSF treatment were observed except for moderate bone pain noted in four of the donors. A 10-month-old donor developed a papular, erythematous eruption 3 weeks after mobilization of stem cells, which resolved completely over 4 weeks. 37 
Apheresis procedure
Venous access was secured on or before the day of the procedure and the device was removed soon after. Venipuncture of both antecubital veins was used in eight donors while a central venous line was necessary in the other 17 donors (all the children and three adults) in order to ensure an adequate blood flow during the procedure. When used, the central line was placed percutaneously in the femoral vein according to the technique described previously. 38, 39 PBSC collections were performed on day 5 of G-CSF mob- ALL = acute lymphoblastic leukemia; CML = chronic myelogenous leukemia; CMML = chronic myelomonocytic leukemia; AML = acute myeloblastic leukemia; CR1 = 1st complete remission; CR2 = 2nd complete remission; RD = refractory disease; RR = refractory relapse; CP = chronic phase; AP = accelerated phase; CMV = cytomegalovirus; TBI = total body irradiation, 12 Gy; CY = cyclophosphamide, 120 mg/kg; BU = busulfan 16 mg/kg; etoposide = 140 mg/m 2 , maximum 1640 mg; CYA = cyclosporine; MTX = methotrexate; PDN = prednisone. ilization using a Cobe Spectra blood cell separator (Cobe, Denver, CO, USA) and large volume leukapheresis (LVL) procedure. 34, 40 A total of 27 leukaphereses were performed on the 25 donors. Two aphereses were necessary in two donors weighing less than the recipient in order to collect the targeted cell dose (4 × 10 6 CD34 + cells/kg of the recipient body weight). No life-threatening complications occurred during catheter insertion or during the apheresis. Only minor episodes of hypocalcemia were observed during the collection procedure. Moderate thrombocytopenia (platelet counts Ͻ100 × 10 9 /l) occurred in six donors and in another four, the hematocrit dropped below 28% after the apheresis, but no transfusion support was necessary. Pre-and post-LVL blood counts and apheresis cell yields are shown in Table 2 .
Transplantation procedure
After completion of conditioning therapy 2.5-32.8 (median 6.9) × 10 6 CD34 + cells per kg of recipient body weight were infused. Numbers of T and NK cells contained in the PBSC grafts are shown in Table 2 . Conditioning regimens are summarized in Table 1 . The day of infusion was defined as day 0. Standard prophylactic antibiotics were started if the ANC was Ͻ0.5 × 10 9 /l and fever Ͼ38°C developed, and were maintained until neutropenia resolved. Empiric amphotericin was added if fever persisted after 4-5 days of antibiotic treatment in a neutropenic patient. Prophylactic acyclovir was given to all patients to prevent HSV and CMV reactivation/infection. GVHD prophylaxis regimens 41, 42 are shown in Table 1 . Cyclosporine (CYA) was maintained until day 180 and discontinued thereafter if no GVHD was present. The patient who received a syngeneic PBSCT did not receive any post-transplant immunosuppression. No patient received G-CSF post transplant.
Evaluation and definitions
Patients were closely followed and clinically evaluated daily. Neutrophil engraftment was defined as the first day of an ANC Ͼ0.5 × 10 9 /l that was maintained for 3 consecutive days. Platelet engraftment was defined as the first day of a platelet count Ͼ20 × 10 9 /l that was maintained for 3 consecutive days without requiring transfusion. Hospital stay was defined as days from day 0 to day of hospital discharge. Acute GVHD was diagnosed clinically and by pathological examination of a skin biopsy when required and graded using standard criteria. [43] [44] [45] [46] Chronic GVHD was initially evaluated at days 80-100 in surviving patients and graded according to the clinicopathological classification of GVHD as limited (clinical or subclinical) or extensive. 47 Evaluation included a complete physical examination, Schrimer's tear test, pulmonary function tests and oral mucosal and skin biopsy from the affected area or posterior iliac crest if no affected areas were present. Patients were clinically followed thereafter and new tests were performed as needed. The patient who received a syngeneic transplant was considered inevaluable for either acute or chronic GVHD.
Bone Marrow Transplantation
Statistical analysis
Data shown are the median and range. Comparisons between median recovery times were done by the log rank test. The Kaplan-Meier model was used for estimation of overall survival (OS), event-free survival (EFS), and relapse curves. 48 
Results
Engraftment and clinical outcome
All patients engrafted neutrophils and all but one patient who died on day 9 post transplant recovered their platelet counts. Median time to neutrophil and platelet engraftment was 10 (range 7-18) and 12 (range 7-25) days, respectively. In 24 evaluable patients a platelet count Ͼ50 ϫ 10 9 /l was achieved at 15 (range 9-40) days post transplant, respectively. No statistically significant differences were found in the median time for neutrophil or platelet recovery related to the dose of CD34 + cells (Ͻ5 or у5 ϫ 10 6 per kg of recipient body weight) or to the GVHD prophylaxis given (CYA ± MTX). The median number of RBC and platelet units transfused was 3 (range 0-13) and 3 (0-30), respectively. Patients received prophylactic antibiotics for neutropenic fever for 4-18 days (median 9) and 10 infectious episodes were documented in nine patients (five bacterial, four viral, and one fungal). Three patients died in the early post-transplant period before being discharged from the hospital (days 9, 27 and 31, respectively). For the remaining patients, the median time as an inpatient was 25 days (range 14-52).
Graft-versus-host disease (GVHD)
Acute GVHD grade уII developed in 10 of 24 evaluable patients (42%), at days 7-30 (median 11) post transplant. Acute GVHD grade III and IV developed in two and three patients, respectively. Probability of acute GVHD grade уII was 62% at day 30. At day 100, five of 21 evaluable patients (24%) presented with chronic GVHD, three limited and two extensive. At 1 year after transplant, two additional patients were diagnosed with extensive chronic GVHD. Median follow-up of all patients evaluable for chronic GVHD is now 748 days (range 106-2071). Probability of chronic GVHD was 17% at day 100, 21% at 1 year and 29% after the first year post PBSCT.
Relapse and survival
Five of 23 patients transplanted for a malignant disease (22%) relapsed between 75 and 320 days after PBSCT (median 110) and four of them died. The last patient underwent a second PBSCT from a different HLA-identical sibling donor, after conditioning with busulfan (16 mg/kg) and melphalan (100 mg/m 2 ). He is now at 1100 days after his second PBSCT, in complete remission, and with extensive chronic GVHD.
Eight patients (32%) died at days 9 to 330 (median 113) after PBSCT. Causes of death included acute GVHD in Bone Marrow Transplantation two patients (days 27 and 31), GVHD and disseminated aspergillosis in one (day 120), veno-occlusive disease in one (day 9) and relapse in four (days 105, 140, 164 and 330). Transplant-related mortality was 16%. Currently, median follow-up for the entire group of patients is 558 (9-2071) days. No deaths have been reported beyond 1 year post transplant. Probabilities of overall survival (OS) and event-free survival (EFS) for the entire group of patients at 5 years are 68% and 64%, respectively. The two patients transplanted for a non-malignant disease are alive and disease-free with full donor chimerism. No relapses have occurred beyond 1 year after PBSCT in the patients transplanted for a malignant disease. Five-year probability of OS, EFS, and relapse for the group of patients with hematological malignancies are 59%, 53% and 24%, respectively (Figure 1 ). Probability of EFS and relapse are 80% and 20%, respectively for patients with ALL transplanted in CR1 and 42% and 25% for patients with ALL transplanted in уCR2 (Figure 2 ).
Discussion
Currently, PBSC technology is being used at several institutions as the first-line transplantation approach in adults with hematological malignancies. The development and application of this procedure has been much slower in the pediatric population, mainly due to ethical questions and technical difficulties involving mobilization and collection procedures. In our experience, mobilization and collection of peripheral blood hematopoietic progenitor cells was easily and safely performed in pediatric donors, even those of very low weight. G-CSF at doses of 10 g/kg/day mobilized enough progenitor cells in healthy children without serious side-effects. The efficacy and short-term safety of G-CSF mobilization in a normal pediatric population have been confirmed in other studies. 17, 19, [23] [24] [25] [26] The feasibility of reliable venous access is an additional problem involving blood product donations in the pediatric population. Since antecubital veins in small children usually do not have large enough diameters to ensure the high flow blood rates necessary for apheresis, different methods of central access have been used to overcome this problem. Other groups have used the radial artery, reporting a low incidence of complications related to the insertion and apheresis procedure. 20, 23 At our institution, percutaneous femoral catheters were successfully and safely used for collection of PBSC products in child and adult donors without major problems. Complications relating to the LVL procedure were minor and manageable and usually a single procedure was needed. After PBSC collection a significant drop in platelet count was noted in several donors. None of them was clinically affected and all recovered completely without intervention. This effect has been associated with not only the apheresis procedure but with the administration of G-CSF. [49] [50] [51] An increment in the splenic volume has been documented in healthy adult donors undergoing G-CSF mobilization 52 which may also contribute to the peripheral thrombocytopenia. On the other hand, thrombotic events secondary to enhanced platelet aggregation with an increment in platelet count and development of a hypercoagulable state have been described in patients and donors treated with G-CSF. [53] [54] [55] Therefore, donors need to be followed carefully, monitoring platelet counts during and after PBSC mobilization and collection procedures.
Ethical issues of this technology arise since there are no defined criteria for PBSC donation in children, and safety of the procedure for pediatric donors has not been totally addressed in the literature. According to our experience, the risks posed by PBSC donation in healthy pediatric donors are acceptable and no higher than the risks involved in marrow harvesting. 56 Since PBSC is a special situation fundamental in saving the life of the recipient, children can be allowed to donate, as is the case with bone marrow donation. However, to ensure the ethical standing of the procedure it should be performed under appropriate protocols. These should be reviewed and approved by institutional ethical committees and parents should be given the opportunity to exercise informed consent or refusal.
The advantages of PBSCT allowing a faster post-transplant recovery have been previously reported in several studies involving pediatric patients. 18, 20, 21 Similarly, in a study performed recently at our institution, the outcome of a group of pediatric patients which underwent allogeneic BMT for the treatment of ALL and a similar group of patients which received allogeneic PBSCT was compared and significantly faster engraftment was found in the PBSCT group. 57 An inverse correlation between the CD34 + cell dose given, the post-transplant administration of MTX and the kinetics of engraftment has been noted by others. 10 In our series such a correlation was not statistically proven, probably due to the small size of our patient population. Miflin et al 10 found that a dose of 4 ϫ 10 6 CD34 + cells per kg of recipient body weight ensures engraftment in allo-PBSC transplants. However, patients receiving lower doses of CD34 + cells were also able to achieve a rapid engraftment. 10 The fast establishment of complete chimerism in allo-PBSCT is thought to mediate an enhanced graftversus-leukemia effect through rapid clearance of residual host cells. [58] [59] [60] [61] This effect could constitute an additional advantage of PBSC grafts; however, most clinical studies have failed to find a clear correlation between allo-PBSCT and reduced risk of disease recurrence. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] While the reported incidence of acute GVHD with PBSCT is similar or lower compared to BMT, 18, 20, 21, 57 several authors have found an increased rate of chronic GVHD after allo-PBSCT.
8,9,12-14, 21 Levine et al 21 found an increased rate of chronic GVHD of up to 75% at 1 year after PBSCT in pediatric patients. In the present report, the probability of chronic GVHD at 1 year was 20%, similar to that found 20 by the Watanabe and Kawano group. However, our series included a small number of patients. In a previous publication we found a similar incidence and severity of chronic GVHD in a group of patients receiving PBSCT and a historical group given a BMT, 57 as also reported by Li et al. 18 The higher rate of chronic GVHD which has been found in some studies associated with this procedure is of concern, but despite differences in the incidence of GVHD, reported EFS and OS after PBSCT are similar in all the previous studies. 18, 20, 21, 57 PBSCT can provide important advantages for the recipient, especially in the early post-transplant period, accelerating bone marrow recovery and decreasing toxic effects of the transplant. Also, G-CSF mobilization and collection can be easily performed and well tolerated in healthy children without major complications, yielding enough numbers of progenitor cells and avoiding the risks and discomfort associated with bone marrow harvesting. However, whether allogeneic PBSCT in the pediatric population gives similar or higher rates of chronic GVHD, decreases the risk of disease recurrence or provides any long-term survival advantage over BMT needs to be addressed in further studies. To date, it is too early to give any data recommending or contraindicating the procedure in children. Risks and benefits for both donor and recipient should be evaluated in the setting of appropriate clinical trials that allow ethical issues to be reviewed.
